HMGCR抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue lysate, Primary antibody: P08402(HMGCR Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P08402(HMGCR Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

**Background of HMGCR Antibodies**

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) is a key enzyme in the cholesterol biosynthesis pathway, targeted by statins to lower cholesterol levels. Autoantibodies against HMGCR were first identified in 2009 and are strongly associated with immune-mediated necrotizing myopathy (IMNM), particularly in statin-exposed individuals. These antibodies are detected in approximately 6% of idiopathic inflammatory myopathy cases and are a hallmark of statin-associated autoimmune myopathy.

The pathogenesis involves statins upregulating HMGCR expression in muscle cells, potentially triggering an autoimmune response in genetically susceptible individuals (e.g., those with *HLA-DRB1* alleles). HMGCR antibodies are IgG-specific and correlate with disease severity, aiding diagnosis when combined with clinical features like proximal muscle weakness, elevated creatine kinase, and muscle necrosis on biopsy.

Testing for HMGCR antibodies (via ELISA or immunoprecipitation) is crucial for differentiating IMNM from other myopathies. Treatment typically involves immunosuppressants (e.g., corticosteroids, rituximab) and statin discontinuation. Research continues to clarify mechanisms linking statins, autoimmunity, and muscle injury, enhancing diagnostic and therapeutic strategies.